Received Sep 25, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | UNK | Y020300 | — |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | Y019319 | — |
No adverse events; wrong vaccine administered; A HCP called to report an AE involving VARIVAX and PROQUAD. The HCP stated that the facility doctor ordered separate doses of MMR II and VARIVAX to be administered to a patient on 09/22/2025, but the patient inadvertently received VARIVAX and PROQUAD; This spontaneous report was received from a medical assistant concerning a 1-year-old female patient. The patient's pertinent medical history, past drug reactions or allergies, concurrent conditions and concomitant therapies were not provided. The health care professional (HCP) stated that the facility doctor ordered separate doses of Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine (MMR II) and Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX) to be administered to a patient on 22-SEP-2025, but the patient inadvertently received Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX) (lot #Y019319, expiration date: 21-NOV-2026) (0.5mL/once) and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD), (lot #Y020300, expiration date: 09-JUN-2026) (0.5m /once). Both vaccines were administered as prophylaxis (dose, anatomical location and route were not reported) on 22-SEP-2025 instead. The patient did not receive the individual dose of Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine (MMR II) as ordered. The HCP stated the patient did not experience any other adverse issues or side effect from the administered vaccines. The vaccines were reconstituted with sterile diluent (MERCK STERILE DILUENT) (lot number and expiration date not reported). The operator of device was HCP. Lot # is being requested and will be submitted if received.
sterile diluent